MENY

Gällande vårdprogram livmoderkroppscancer

Fastställt av Regionala cancercentrum i samverkan 2018-06-27.

21. Referenser

1.      Cancer i siffror 2009, Socialstyrelsen.

2.      Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. International journal of cancer Journal international du cancer. 2001;91(3):421-30.

3.      Potischman N, Swanson CA, Brinton LA, McAdams M, Barrett RJ, Berman ML, et al. Dietary associations in a case-control study of endometrial cancer. Cancer causes & control : CCC. 1993;4(3):239-50.

4.      Jain MG, Rohan TE, Howe GR, Miller AB. A cohort study of nutritional factors and endometrial cancer. European journal of epidemiology. 2000;16(10):899-905.

5.      Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491-505.

6.      Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. Journal of the National Cancer Institute. 1985;74(4):741-5.

7.      Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. British journal of cancer. 1983;47(6):749-56.

8.      Epstein E, Lindqvist PG, Geppert B, Olsson H. A population-based cohort study on sun habits and endometrial cancer. British journal of cancer. 2009;101(3):537-40.

9.      Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. International journal of cancer Journal international du cancer. 2002;98(6):912-5.

10.    Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Jama. 1987;257(6):796-800.

11.    Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute. 1999;91(13):1131-7.

12.    Beral V, Bull D, Reeves G, Million Women Study C. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543-51.

13.    Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PloS one. 2013;8(11):e78016.

14.    Epstein E, Lindqvist PG, Olsson H. A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. International journal of cancer Journal international du cancer. 2009;125(2):421-5.

15.    van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343(8895):448-52.

16.    Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Doren M, et al. The endometrium in breast cancer patients on tamoxifen. Archives of gynecology and obstetrics. 2000;263(4):170-7.

17.    Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet. 2000;356(9233):881-7.

18.    Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. Nature reviews Gastroenterology & hepatology. 2015;12(2):88-97.

19.    Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. International journal of cancer Journal international du cancer. 1995;64(6):430-3.

20.    Watson P, Butzow R, Lynch HT, Mecklin JP, Jarvinen HJ, Vasen HF, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic oncology. 2001;82(2):223-8.

21.    Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database. Disease markers. 2004;20(4-5):269-76.

22.    Mutch D, Denny L, Quinn M, Oncology FCoG. Hereditary gynecologic cancers. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2014;124(3):189-92.

23.    Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Familial cancer. 2008;7(1):53-8.

24.    Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta obstetricia et gynecologica Scandinavica. 2011;90(5):437-44.

25.    Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(2):209-17.

26.    Bachmann LM, ter Riet G, Clark TJ, Gupta JK, Khan KS. Probability analysis for diagnosis of endometrial hyperplasia and cancer in postmenopausal bleeding: an approach for a rational diagnostic workup. Acta obstetricia et gynecologica Scandinavica. 2003;82(6):564-9.

27.    Clark TJ, Barton PM, Coomarasamy A, Gupta JK, Khan KS. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG : an international journal of obstetrics and gynaecology. 2006;113(5):502-10.

28.    Gupta JK, Chien PF, Voit D, Clark TJ, Khan KS. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta obstetricia et gynecologica Scandinavica. 2002;81(9):799-816.

29.    Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. Jama. 1998;280(17):1510-7.

30.    Epstein E, Jamei B, Lindqvist PG. High risk of cervical pathology among women with postmenopausal bleeding and endometrium <or=4.4 mm: long-term follow-up results. Acta obstetricia et gynecologica Scandinavica. 2006;85(11):1368-74.

31.    Epstein E, Valentin L. Managing women with post-menopausal bleeding. Best practice & research Clinical obstetrics & gynaecology. 2004;18(1):125-43.

32.    Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta obstetricia et gynecologica Scandinavica. 2001;80(12):1131-6.

33.    Antonsen SL, Jensen LN, Loft A, Berthelsen AK, Costa J, Tabor A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecologic oncology. 2013;128(2):300-8.

34.    Celik C, Ozdemir S, Kiresi D, Emlik D, Tazegul A, Esen H. Evaluation of cervical involvement in endometrial cancer by transvaginal sonography, magnetic resonance imaging and frozen section. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2010;30(3):302-7.

35.    Cicinelli E, Marinaccio M, Barba B, Tinelli R, Colafiglio G, Pedote P, et al. Reliability of diagnostic fluid hysteroscopy in the assessment of cervical invasion by endometrial carcinoma: a comparative study with transvaginal sonography and MRI. Gynecologic oncology. 2008;111(1):55-61.

36.    Epstein E, Blomqvist L. Imaging in endometrial cancer. Best practice & research Clinical obstetrics & gynaecology. 2014;28(5):721-39.

37.    Ortoft G, Dueholm M, Mathiesen O, Hansen ES, Lundorf E, Moller C, et al. Preoperative staging of endometrial cancer using TVS, MRI, and hysteroscopy. Acta obstetricia et gynecologica Scandinavica. 2013;92(5):536-45.

38.    Ozdemir S, Celik C, Emlik D, Kiresi D, Esen H. Assessment of myometrial invasion in endometrial cancer by transvaginal sonography, Doppler ultrasonography, magnetic resonance imaging and frozen section. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(6):1085-90.

39.    Savelli L, Ceccarini M, Ludovisi M, Fruscella E, De Iaco PA, Salizzoni E, et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2008;31(5):560-6.

40.    Van Holsbeke C, Ameye L, Testa AC, Mascilini F, Lindqvist P, Fischerova D, et al. Development and external validation of new ultrasound-based mathematical models for preoperative prediction of high-risk endometrial cancer. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2014;43(5):586-95.

41.    Akbayir O, Corbacioglu A, Numanoglu C, Guleroglu FY, Ulker V, Akyol A, et al. Preoperative assessment of myometrial and cervical invasion in endometrial carcinoma by transvaginal ultrasound. Gynecologic oncology. 2011;122(3):600-3.

42.    Alcazar JL, Galvan R, Albela S, Martinez S, Pahisa J, Jurado M, et al. Assessing myometrial infiltration by endometrial cancer: uterine virtual navigation with three-dimensional US. Radiology. 2009;250(3):776-83.

43.    Fishman A, Altaras M, Bernheim J, Cohen I, Beyth Y, Tepper R. The value of transvaginal sonography in the preoperative assessment of myometrial invasion in high and low grade endometrial cancer and in comparison to frozen section in grade 1 disease. European journal of gynaecological oncology. 2000;21(2):128-30.

44.    Mascilini F, Testa AC, Van Holsbeke C, Ameye L, Timmerman D, Epstein E. Evaluating myometrial and cervical invasion in women with endometrial cancer: comparing subjective assessment with objective measurement techniques. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2013;42(3):353-8.

45.    Eriksson LS, Lindqvist PG, Floter Radestad A, Dueholm M, Fischerova D, Franchi D, et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;45(4):476-82.

46.    Karlsson B, Norstrom A, Granberg S, Wikland M. The use of endovaginal ultrasound to diagnose invasion of endometrial carcinoma. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1992;2(1):35-9.

47.    Epstein E, Van Holsbeke C, Mascilini F, Masback A, Kannisto P, Ameye L, et al. Gray-scale and color Doppler ultrasound characteristics of endometrial cancer in relation to stage, grade and tumor size. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2011;38(5):586-93.

48.    Jantarasaengaram S, Praditphol N, Tansathit T, Vipupinyo C, Vairojanavong K. Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2014;43(5):569-74.

49.    Ruangvutilert P, Sutantawibul A, Sunsaneevithayakul P, Boriboonhirunsarn D, Chuenchom T. Accuracy of transvaginal ultrasound for the evaluation of myometrial invasion in endometrial carcinoma. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2004;87(1):47-52.

50.    Sawicki W, Spiewankiewicz B, Stelmachow J, Cendrowski K. The value of ultrasonography in preoperative assessment of selected prognostic factors in endometrial cancer. European journal of gynaecological oncology. 2003;24(3-4):293-8.

51.    Szantho A, Szabo I, Csapo ZS, Balega J, Demeter A, Papp Z. Assessment of myometrial and cervical invasion of endometrial cancer by transvaginal sonography. European journal of gynaecological oncology. 2001;22(3):209-12.

52.    Hardesty LA, Sumkin JH, Nath ME, Edwards RP, Price FV, Chang TS, et al. Use of preoperative MR imaging in the management of endometrial carcinoma: cost analysis. Radiology. 2000;215(1):45-9.

53.    Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999;212(3):711-8.

54.    Frei KA, Kinkel K. Staging endometrial cancer: role of magnetic resonance imaging. Journal of magnetic resonance imaging : JMRI. 2001;13(6):850-5.

55.    Beddy P, Moyle P, Kataoka M, Yamamoto AK, Joubert I, Lomas D, et al. Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2012;262(2):530-7.

56.    Wu LM, Xu JR, Gu HY, Hua J, Haacke EM, Hu J. Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: a pooled analysis of prospective studies. European radiology. 2013;23(2):435-49.

57.    Levy A, Medjhoul A, Caramella C, Zareski E, Berges O, Chargari C, et al. Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: a review. Journal of magnetic resonance imaging : JMRI. 2011;33(5):1020-7.

58.    Andreano A, Rechichi G, Rebora P, Sironi S, Valsecchi MG, Galimberti S. MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis. European radiology. 2014;24(6):1327-38.

59.    Frei KA, Kinkel K, Bonel HM, Lu Y, Zaloudek C, Hricak H. Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis. Radiology. 2000;216(2):444-9.

60.    Barwick TD, Rockall AG, Barton DP, Sohaib SA. Imaging of endometrial adenocarcinoma. Clinical radiology. 2006;61(7):545-55.

61.    Duncan KA, Drinkwater KJ, Frost C, Remedios D, Barter S. Staging cancer of the uterus: a national audit of MRI accuracy. Clinical radiology. 2012;67(6):523-30.

62.    Kinkel K, Forstner R, Danza FM, Oleaga L, Cunha TM, Bergman A, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. European radiology. 2009;19(7):1565-74.

63.    Manfredi R, Mirk P, Maresca G, Margariti PA, Testa A, Zannoni GF, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372-8.

64.    Mitamura T, Watari H, Todo Y, Kato T, Konno Y, Hosaka M, et al. Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments. Journal of gynecologic oncology. 2014;25(4):301-5.

65.    Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375(9721):1165-72.

66.    Berman ML, Ballon SC, Lagasse LD, Watring WG. Prognosis and treatment of endometrial cancer. American journal of obstetrics and gynecology. 1980;136(5):679-88.

67.    Sayin NC, Varol FG, Yuce MA, Kaplan P, Ahmet N, Sut N, et al. Do routine preoperative imaging techniques facilitate the operation in endometrial cancer? Archives of gynecology and obstetrics. 2009;280(2):211-5.

68.    Bansal N, Herzog TJ, Brunner-Brown A, Wethington SL, Cohen CJ, Burke WM, et al. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Gynecologic oncology. 2008;111(2):208-12.

69.    Basu S, Li G, Alavi A. PET and PET-CT imaging of gynecological malignancies: present role and future promise. Expert review of anticancer therapy. 2009;9(1):75-96.

70.    Kakhki VR, Shahriari S, Treglia G, Hasanzadeh M, Zakavi SR, Yousefi Z, et al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(9):1536-43.

71.    Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecologic oncology. 2008;108(3):486-92.

72.    Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. European radiology. 2009;19(6):1529-36.

73.    Beddy P, O'Neill AC, Yamamoto AK, Addley HC, Reinhold C, Sala E. FIGO staging system for endometrial cancer: added benefits of MR imaging. Radiographics : a review publication of the Radiological Society of North America, Inc. 2012;32(1):241-54.

74.    Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology. 2013;266(3):717-40.

75.    Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89(8):1765-72.

76.    Alfhaily F, Ewies AA. The first-line investigation of postmenopausal bleeding: transvaginal ultrasound scanning and endometrial biopsy may be enough. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(5):892-5.

77.    Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecologic oncology. 2000;76(3):287-90.

78.    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56(2):403-12.

79.    Lacey JV, Jr., Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63(1):39-44.

80.    Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds): WHO classification of tumours of female reproductive organs. 4th ed. IARC, 2014. ISBN 978-92-832-2435-8.

81.    Rosai J (ed): Rosai and Ackerman’s Surgical Pathology, Ninth Edition, Mosby, 2004. ISBN 13: 978-0-323-01342-0.

82.    Symonds I. Ultrasound, hysteroscopy and endometrial biopsy in the investigation of endometrial cancer. Reviews in Gynecol Practice 2003;3:11-15. .

83.    Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. The American journal of surgical pathology. 2013;37(6):874-81.

84.    Chiang S, Soslow RA. Updates in diagnostic immunohistochemistry in endometrial carcinoma. Seminars in diagnostic pathology. 2014;31(3):205-15.

85.    Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Advances in anatomic pathology. 2011;18(6):415-37.

86.    Creasman W. Revised FIGO staging for carcinoma of the endometrium. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009;105(2):109.

87.    Sorbe B. Predictive and prognostic factors in definition of risk groups in endometrial carcinoma. ISRN obstetrics and gynecology. 2012;2012:325790.

88.    Suehiro Y, Okada T, Okada T, Anno K, Okayama N, Ueno K, et al. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(11):3354-61.

89.    Larson DM, Berg R, Shaw G, Krawisz BR. Prognostic significance of DNA ploidy in endometrial cancer. Gynecologic oncology. 1999;74(3):356-60.

90.    Njolstad TS, Trovik J, Hveem TS, Kjaereng ML, Kildal W, Pradhan M, et al. DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. British journal of cancer. 2015;112(10):1656-64.

91.    Pradhan M, Davidson B, Abeler VM, Danielsen HE, Trope CG, Kristensen GB, et al. DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium. Virchows Archiv : an international journal of pathology. 2012;461(3):291-8.

92.    Green RW, Engblom S, Baldetorp B, Hartman L, Masback A, Bjurberg M. Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study. Acta obstetricia et gynecologica Scandinavica. 2015;94(10):1064-73.

93.    Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. British journal of cancer. 2006;94(5):642-6.

94.    Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecologic oncology. 2005;98(2):274-80.

95.    Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecologic oncology. 1991;40(1):55-65.

96.    Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006;95 Suppl 1:S105-43.

97.    Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(2):269-73.

98.    Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404-11.

99.    Briet JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecologic oncology. 2005;96(3):799-804.

100.  Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N, Thomas G, Covens A, et al. Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. American journal of clinical pathology. 2008;129(6):912-7.

101.  Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(7):1234-41.

102.  Feltmate CM, Duska LR, Chang Y, Flynn CE, Nikrui N, Kiggundu E, et al. Predictors of recurrence in surgical stage II endometrial adenocarcinoma. Gynecologic oncology. 1999;73(3):407-11.

103.  Prat J. Prognostic parameters of endometrial carcinoma. Human pathology. 2004;35(6):649-62.

104.  Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecologic oncology. 2002;84(3):437-42.

105.  Greven KM, Corn BW, Case D, Purser P, Lanciano RM. Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation? International journal of radiation oncology, biology, physics. 1997;39(2):413-8.

106.  Simpkins F, Papadia A, Kunos C, Michener C, Frasure H, AbuShahin F, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(1):98-104.

107.  Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstetrics and gynecology. 1987;70(2):216-9.

108.  Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer research. 2002;62(3):881-6.

109.  Nguyen TV, Petereit DG. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecologic oncology. 1998;71(2):196-203.

110.  Skov BG, Broholm H, Engel U, Franzmann MB, Nielsen AL, Lauritzen AF, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1997;16(1):33-7.

111.  Bergeron C, Nogales FF, Masseroli M, Abeler V, Duvillard P, Muller-Holzner E, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. The American journal of surgical pathology. 1999;23(9):1102-8.

112.  Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecologic oncology. 2011;120(1):43-6.

113.  Edris F, Vilos GA, Al-Mubarak A, Ettler HC, Hollett-Caines J, Abu-Rafea B. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. Journal of minimally invasive gynecology. 2007;14(1):68-73.

114.  Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2009;25(10):683-91.

115.  Horvath LE, Yordan E, Malhotra D, Leyva I, Bortel K, Schalk D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. Journal of oncology practice / American Society of Clinical Oncology. 2010;6(6):e21-6.

116.  Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. Journal of cancer education : the official journal of the American Association for Cancer Education. 2008;23(4):235-7.

117.  Greer HO, Frederick PJ, Falls NM, Tapley EB, Samples KL, Kimball KJ, et al. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(8):1321-5.

118.  Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Annals of surgical oncology. 2011;18(8):2116-25.

119.  Lamb BW, Green JS, Benn J, Brown KF, Vincent CA, Sevdalis N. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. Journal of the American College of Surgeons. 2013;217(3):412-20.

120.  Mourits MJ, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. The Lancet Oncology. 2010;11(8):763-71.

121.  Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(32):5337-42.

122.  Palomba S, Falbo A, Russo T, Zullo F. Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer. Gynecologic oncology. 2009;114(1):135-6.

123.  Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(7):695-700.

124.  Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. American journal of obstetrics and gynecology. 2008;199(4):360 e1-9.

125.  Seamon LG, Cohn DE, Richardson DL, Valmadre S, Carlson MJ, Phillips GS, et al. Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstetrics and gynecology. 2008;112(6):1207-13.

126.  Gehrig PA, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggess JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? Gynecologic oncology. 2008;111(1):41-5.

127.  Tinelli R, Litta P, Meir Y, Surico D, Leo L, Fusco A, et al. Advantages of laparoscopy versus laparotomy in extremely obese women (BMI>35) with early-stage endometrial cancer: a multicenter study. Anticancer research. 2014;34(5):2497-502.

128.  Farthing A, Chatterjee J, Joglekar-Pai P, Dorney E, Ghaem-Maghami S. Total laparoscopic hysterectomy for early stage endometrial cancer in obese and morbidly obese women. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2012;32(6):580-4.

129.  Helm CW, Arumugam C, Gordinier ME, Metzinger DS, Pan J, Rai SN. Laparoscopic surgery for endometrial cancer: increasing body mass index does not impact postoperative complications. Journal of gynecologic oncology. 2011;22(3):168-76.

130.  Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecologic oncology. 2006;103(2):714-8.

131.  Khoury-Collado F, Murray MP, Hensley ML, Sonoda Y, Alektiar KM, Levine DA, et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecologic oncology. 2011;122(2):251-4.

132.  Ballester M, Dubernard G, Lecuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). The Lancet Oncology. 2011;12(5):469-76.

133.  Kucera H, Knocke TH, Kucera E, Potter R. Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta obstetricia et gynecologica Scandinavica. 1998;77(10):1008-12.

134.  Nguyen C, Souhami L, Roman TN, Clark BG. High-dose-rate brachytherapy as the primary treatment of medically inoperable stage I-II endometrial carcinoma. Gynecologic oncology. 1995;59(3):370-5.

135.  The GEC ESTRO handbook of brachytherapy 2002. Ed: Gerbault A, Pötter R, Mazeron JJ, van Limbergen E. ISBN 90-804532-6.

136.  Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstetrics and gynecology. 1980;56(4):419-27.

137.  Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2004;92(3):744-51.

138.  Group AES, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137-46.

139.  Martinez AA, Weiner S, Podratz K, Armin AR, Stromberg JS, Stanhope R, et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecologic oncology. 2003;90(3):537-46.

140.  Kong A, Simera I, Collingwood M, Williams C, Kitchener H, Cochrane Gynaecological Cancer G. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2007;18(10):1595-604.

141.  Nout RA, van de Poll-Franse LV, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(13):1692-700.

142.  Onsrud M, Cvancarova M, Hellebust TP, Trope CG, Kristensen GB, Lindemann K. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(31):3951-6.

143.  Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816-23.

144.  Creutzberg CL, Nout RA, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. International journal of radiation oncology, biology, physics. 2011;81(4):e631-8.

145.  Ortoft G, Hansen ES, Bertelsen K. Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(8):1429-37.

146.  Small W, Jr., Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. International journal of radiation oncology, biology, physics. 2008;71(2):428-34.

147.  Lin LL, Grigsby PW, Powell MA, Mutch DG. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. International journal of radiation oncology, biology, physics. 2005;63(2):500-4.

148.  Huh WK, Straughn JM, Jr., Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007;17(4):886-9.

149.  Poulsen HK, Jacobsen M, Bertelsen K et al. Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases. Int J Gynecol Cancer 1996;6:38.

150.  Hogberg T, Fredstorp-Lidebring M, Alm P, Baldetorp B, Larsson G, Ottosen C, et al. A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2004;14(3):437-50.

151.  Mariani A, Dowdy SC, Cliby WA, Haddock MG, Keeney GL, Lesnick TG, et al. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecologic oncology. 2006;101(2):200-8.

152.  Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale F, Hunter RE. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. International journal of radiation oncology, biology, physics. 1992;24(2):229-33.

153.  Corn BW, Lanciano RM, Greven KM, Schultz DJ, Reisinger SA, Stafford PM, et al. Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. International journal of radiation oncology, biology, physics. 1992;24(2):223-7.

154.  Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? British journal of cancer. 2009;101(2):244-9.

155.  Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. The Cochrane database of systematic reviews. 2011(10):CD003175.

156.  Hogberg T, Rosenberg P, Kristensen G. et al. A randomized phase-III study on adjuvant treatmentwith radiation (RT)+/- chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007;25:5503.

157.  Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. European journal of cancer. 2010;46(13):2422-31.

158.  Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemoterapy for advanced endometrial cancer (Review). The Cochrane Library 2014, Issue 5.

159.  Miller D, et al. Randomized phase III non-inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinom: a Gynecologic Oncology group study. SGO 2012; Late-Breaking Abstract 1.

160.  Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(16):2259-65.

161.  Milam MR, Frumovitz M, dos Reis R, Broaddus RR, Bassett RL, Jr., Ramirez PT. Preoperative lymph-vascular space invasion is associated with nodal metastases in women with early-stage cervical cancer. Gynecologic oncology. 2007;106(1):12-5.

162.  Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2013;129(1):22-7.

163.  Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. The Cochrane database of systematic reviews. 2010(9):CD007291.

164.  Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS, Gynecologic Oncology Group S. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(4):587-92.

165.  Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Gallo M. Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas. 2015;82(3):296-8.

166.  Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. European journal of cancer. 2014;50(9):1628-37.

167.  Marnitz S, Kohler C. Current therapy of patients with endometrial carcinoma. A critical review. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al]. 2012;188(1):12-20.

168.  Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstetrics and gynecology. 1989;74(6):934-43.

169.  Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecologic oncology. 1999;75(1):99-102.

170.  Scarabelli C, Campagnutta E, Giorda G, DePiero G, Sopracordevole F, Quaranta M, et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecologic oncology. 1998;70(1):90-3.

171.  Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL, 2nd, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecologic oncology. 2006;103(1):281-7.

172.  Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecologic oncology. 2006;101(2):280-6.

173.  Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecologic oncology. 2003;89(2):201-9.

174.  Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(21):3547-56.

175.  Dunberger G, Lind H, Steineck G, Waldenstrom AC, Nyberg T, Al-Abany M, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. European journal of cancer. 2010;46(3):606-15.

176.  www.swepos.se.

177.  Nationellt vårdprogram för cancerrehabilitering (www.cancercentrum.se).

178.  Tada H, Teramukai S, Fukushima M, Sasaki H. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC cancer. 2009;9:47.

179.  Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani M, et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecologic oncology. 2010;119(1):60-4.

180.  Konno Y, Todo Y, Minobe S, Kato H, Okamoto K, Sudo S, et al. A retrospective analysis of postoperative complications with or without para-aortic lymphadenectomy in endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(2):385-90.

181.  Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. Journal of the National Cancer Institute. 2008;100(23):1707-16.

182.  group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125-36.

183.  Baekelandt MM, Castiglione M, Group EGW. Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008;19 Suppl 2:ii19-20.

184.  National Comprehensive Cancer network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. V.1.2010.

185.  Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecologic oncology. 2006;101(3):520-9.

186.  Lajer H, Jensen MB, Kilsmark J, Albaek J, Svane D, Mirza MR, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(8):1307-20.

187.  Smith CJ, Heeren M, Nicklin JL, Perrin LC, Land R, Crandon AJ, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecologic oncology. 2007;107(1):124-9.